Iradimed Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
12.0%projected annual EPS growth
Analyst Coverage
2analysts covering
FY Revenue (est.)
$91.2Mnext fiscal year
FY EPS (est.)
$2.09next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 29 Oct 2026 |
Monitoring Framework
Key Performance Indicators
Quarterly Revenue Quarterly22MTarget: 20000000 to 21000000
GAAP Diluted EPS Quarterly0.5Target: 0.40 to 0.44
Non-GAAP Diluted EPS Quarterly0.5Target: 0.44 to 0.48
Gross Profit Margin Quarterly76.5%
Watch Items
- MRidium 3870 IV Pump Commercial Launch and Adoption
Research as of 19 Jun 2026